Format

Send to

Choose Destination
Cancer Res. 2018 Dec 1;78(23):6561-6574. doi: 10.1158/0008-5472.CAN-18-0330. Epub 2018 Oct 8.

CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human Melanoma.

Author information

1
Department of Dermatology, University of Colorado Denver, Aurora, Colorado.
2
Department of Medicine, University of Colorado Denver, Aurora, Colorado.
3
Department of Dermatology, University of Colorado Denver, Aurora, Colorado. mayumi.fujita@ucdenver.edu.
4
Denver VA Medical Center, Denver, Colorado.
5
Department of Immunology & Microbiology, University of Colorado Denver, Aurora, Colorado.
#
Contributed equally

Abstract

: Cancers are composed of heterogeneous subpopulations with various tumor-initiating capacities, yet key stem cell genes associated with enhanced tumor-initiating capacities and their regulatory mechanisms remain elusive. Here, we analyzed patient-derived xenografts from melanoma, colon, and pancreatic cancer tissues and identified enrichment of tumor-initiating cells in MHC class I-hi cells, where CDK1, a master regulator of the cell cycle, was upregulated. Overexpression of CDK1, but not its kinase-dead variant, in melanoma cells increased their spheroid forming ability, tumorigenic potential, and tumor-initiating capacity; inhibition of CDK1 with pharmacologic agents reduced these characteristics, which was unexplained by the role of CDK1 in regulating the cell cycle. Proteomic analysis revealed an interaction between CDK1 and the pluripotent stem cell transcription factor Sox2. Blockade or knockdown of CDK1 resulted in reduced phosphorylation, nuclear localization, and transcriptional activity of Sox2. Knockout of Sox2 in CDK1-overexpressing cells reduced CDK1-driven tumor-initiating capacity substantially. Furthermore, GSEA analysis of CDK1hi tumor cells identified a pathway signature common in all three cancer types, including E2F, G2M, MYC, and spermatogenesis, confirming a stem-like nature of CDK1hi tumor cells. These findings reveal a previously unrecognized role for CDK1 in regulating tumor-initiating capacity in melanoma and suggest a novel treatment strategy in cancer via interruption of CDK1 function and its protein-protein interactions. SIGNIFICANCE: These findings uncover CDK1 as a new regulator of Sox2 during tumor initiation and implicate the CDK1-Sox2 interaction as a potential therapeutic target in cancer.

PMID:
30297536
PMCID:
PMC6279496
[Available on 2019-12-01]
DOI:
10.1158/0008-5472.CAN-18-0330

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center